Topologic network analysis of drug targets and disease genes. (A) Distribution of platelet drug targets according to the type (group) of drugs with which they are associated (approved or experimental). (B) Proteins were grouped by their number of interactions. Network analysis indicates a higher number of disease-associated genes among well-connected proteins. (C) The datasets of disease proteins and nondisease proteins are presented in box-plots. The number of interactors is shown in a logarithmic scale on the y-axis. Their median is higher in the group of disease proteins compared with nondisease proteins. (D) Topologic network analysis of drug targets reveals an increase in the number of drug targets among highly connected platelet proteins. (E) Drug targets and nondrug targets are presented in box-plots according to their number of interactors. The median is higher in the group of drug targets, indicating enrichment of highly connected proteins in drug targets. (F) Detailed analysis of drug targets distinguished by the type of targeting drug. Proteins associated exclusively with experimental drugs are more likely to have a higher number of interactions compared with targets of approved drugs or both approved and experimental drugs.